Enhance your nephrology practice with CME and tools focused on kidney medicine.
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Quantifying CKD-aP: Tools for Better Care
Is CKD-aP Hiding in Your Dialysis Center?
CKD-aP or Something Else? Decoding the Diagnosis
Improving Sleep and Mental Health in Patients with CKD-aP
The Patient-Clinician Connection in Managing CKD-aP
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
CKD-aP: Beyond the Surface
Kappa-Opioid Settings: Real-World Evidence Insights
CKD-aP Treatment Tool Kit
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Ellie Kelepouris, MD, FACP, FAHA
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Patrick Rossignol, MD, PhD
Potassium Binders in Practice: Clinical Trial Evidence
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
Implementing the SOC Induction Therapies in AAV
Elevating Care for Patients With Severe Renal Disease in AAV
Andreas Kronbichler, MD
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.